Table 3.
Characterization, target indications, drug release pattern, and cytotoxicity of albumin and functionalized albumin nanoparticles prepared by emulsification
| Albumin used | Organic phase and surfactant | Functionalizing or coating agent | Drug or antioxidant loaded | Target indication | Outcome or application† | Reference |
|---|---|---|---|---|---|---|
| HSA in water | Chloroform + ethanol | – | Paclitaxel (PTX) | Breast cancer (MCF-7 cell line) |
|
[19] |
| BSA in NaOH | Castor oil + Span 80 | – | 10-Hydroxycamptothecin (HCPT) | Liver cancer |
|
[74] |
| HSA in water | Chloroform + acetone + cholesterol | Chitosan, PLG-PEG | Teniposide (TS) | Lung cancer (A549 cell line) |
|
[75] |
| BSA in PBS (w1) | Tween 80 (o) Aqueous solution of PLGA (w2) | – | – | – |
|
[76] |
| BSA in water | BmimPF6 + Tween 20 | Folic acid | – | – |
|
[77] |
| BSA in water | n-Butanol + toluene + coconut oil | – | – | – |
|
[78] |
| HSA in water | Ethanol + Tween 80 | – | Carvacrol | Gastric cancer (AGS cell line) |
|
[79] |
Particle diameters are approximate; BmimPF6, 1-butyl-3-methylimidazolium hexafluorophosphate, BSA, bovine serum albumin; DEE, drug entrapment efficiency (approximate); DLC, drug-loading capacity (approximate); HSA, human serum albumin; IC50, half-maximal inhibitory concentration; o, organic phase; PBS, phosphate-buffered saline; PEG, polyethylene glycol; PLG, poly(l-glutamic acid)-g-methoxy; PLGA, poly(d,l-lactic-co-glycolic acid); W1, internal aqueous phase; W2, external aqueous phase; ZP, zeta potential.